Cordycepin - OncoVista Innovative Therapies

Drug Profile

Cordycepin - OncoVista Innovative Therapies

Alternative Names: 3'-deoxyadenosine; OVI-123

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OXiGENE
  • Developer OncoVista Innovative Therapies
  • Class Antifungals; Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Leukaemia

Most Recent Events

  • 13 Sep 2017 No recent reports on development identified - Preclinical for Leukaemia in France (IV)
  • 17 Jun 2016 OXiGENE is now called Mateon Therapeutics
  • 01 Apr 2013 Preclinical development is ongoing in France. Phase I/II trial is still on hold until additional funding is available.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top